Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 212 (ZNF212) is a member of the C2H2-type zinc finger protein family, which primarily functions as a transcription factor and is involved in the regulation of gene expression[10][3][9]. ZNF212 contains three functional domains: a DUF3669 domain (function unknown), a KRAB domain (typically involved in transcriptional repression), and classical C2H2 zinc finger domains (bind DNA)[1]. ZNF212 has been shown to promote genomic integrity by acting directly in DNA repair pathways—specifically, by interacting with TRAIP and NEIL3, participating in the DNA damage response, homologous recombination, and interstrand crosslink repair[2][8]. Loss of ZNF212 results in Purkinje cell death, suggesting a critical role in neural cell survival[1]. ZNF212 may function upstream of certain repair pathways, including NEIL3 and Fanconi anemia pathways[8]. There are currently no direct reports of pharmacological modulators or drugs targeting ZNF212, nor established uses as a biomarker or therapeutic target in disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 212 (ZNF212).